{"nctId":"NCT02833844","briefTitle":"Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia","startDateStruct":{"date":"2017-05-22","type":"ACTUAL"},"conditions":["Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection"],"count":467,"armGroups":[{"label":"Double-Blind Placebo SC QM/Open-Label Evolocumab 420 mg SC QM","type":"EXPERIMENTAL","interventionNames":["Drug: Evolocumab","Drug: Placebo"]},{"label":"Double-Blind Evolocumab 420 mg SC QM/Open-Label Evolocumab 420 mg SC QM","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Evolocumab"]}],"interventions":[{"name":"Evolocumab","otherNames":["EvoMab","Repatha","AMG 145"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female ≥ 18 years of age\n* Known HIV infection with stable HIV therapy for ≥ 6 months\n* Cluster of differentiation 4 (CD4) ≥ 250 cells/mm\\^3 for ≥ 6 months\n* HIV viral load ≤ 50 copies/mL at screening and ≤ 200 copies/mL for ≥ 6 months\n* Subject on stable lipid-lowering therapy for ≥ 4 weeks prior to randomization and not expected to change during the duration of study\n* For subjects with known clinical atherosclerotic cardiovascular disease (ASCVD), fasting LDL-C of ≥ 70 mg/dL or non-high density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dL. For subjects without known clinical ASCVD: fasting LDL-C of ≥ 100 mg/dL or non-HDL-C of ≥ 130 mg/dL\n* Fasting triglycerides ≤ 600 mg/dL (6.8 mmol/L)\n\nExclusion Criteria:\n\n* Taking a combination of background lipid-lowering therapy and HIV therapy known to have significant drug-drug interaction\n* New York Heart Association (NYHA) III or IV heart failure, or last known left ventricular ejection fraction (LVEF) \\< 30%\n* Known opportunistic infection/acquired immunodeficiency syndrome (AIDS) defining illness within 1 year prior to randomization\n* Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft or stroke within 3 months\n* Type 1 diabetes, new-onset or poorly controlled type 2 diabetes\n* Uncontrolled hypertension\n* Taken a cholesteryl ester transfer protein inhibitor in the last 12 months\n* Moderate to severe renal dysfunction\n* Persistent active liver disease or hepatic dysfunction (Stable chronic hepatitis C of at least 1 year duration prior to randomization is allowed)\n* Malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in-situ, or stage 1 prostate carcinoma) within the last 5 years prior to randomization\n\nOther exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in LDL-C at Week 24","description":"Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.68","spread":"2.03"},{"groupId":"OG001","value":"-55.23","spread":"1.52"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in LDL-C at Week 24","description":"Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"3.1"},{"groupId":"OG001","value":"-77.5","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Acheiving LDL-C < 70 mg/dL (1.8 mmol/L) at Week 24","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null},{"groupId":"OG001","value":"73.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an LDL-C Response (50% Reduction of LDL-C From Baseline) at Week 24","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null},{"groupId":"OG001","value":"72.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (HDL-C) at Week 24","description":"Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.86","spread":"1.74"},{"groupId":"OG001","value":"-48.07","spread":"1.31"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24","description":"Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.59","spread":"1.50"},{"groupId":"OG001","value":"-45.14","spread":"1.13"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol (TC) at Week 24","description":"Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.34","spread":"1.40"},{"groupId":"OG001","value":"-35.78","spread":"1.06"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 24","description":"Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.35","spread":"3.34"},{"groupId":"OG001","value":"-16.44","spread":"2.57"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglycerides at Week 24","description":"Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.21","spread":"3.80"},{"groupId":"OG001","value":"-9.25","spread":"2.89"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C at Week 24","description":"Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.73","spread":"1.57"},{"groupId":"OG001","value":"11.08","spread":"1.20"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 24","description":"Least squares mean is from the repeated measures model which includes treatment group, statin stratification factor, scheduled visit and the interaction of treatment with scheduled visit as covariates. (Hepatitis C stratification factor is not included in the model due to low participant numbers.)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.34","spread":"3.54"},{"groupId":"OG001","value":"-9.81","spread":"2.65"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":157},"commonTop":["Diarrhoea","Nasopharyngitis","Back pain","Influenza like illness","Arthralgia"]}}}